89 related articles for article (PubMed ID: 14671397)
1. Peroxisome proliferator-activated receptor-gamma and insulin action: insights from human genetics.
Chatterjee VK
Horm Res; 2003; 60 Suppl 3():51-5. PubMed ID: 14671397
[TBL] [Abstract][Full Text] [Related]
2. Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension.
Barroso I; Gurnell M; Crowley VE; Agostini M; Schwabe JW; Soos MA; Maslen GL; Williams TD; Lewis H; Schafer AJ; Chatterjee VK; O'Rahilly S
Nature; 1999 Dec 23-30; 402(6764):880-3. PubMed ID: 10622252
[TBL] [Abstract][Full Text] [Related]
3. Digenic inheritance of severe insulin resistance in a human pedigree.
Savage DB; Agostini M; Barroso I; Gurnell M; Luan J; Meirhaeghe A; Harding AH; Ihrke G; Rajanayagam O; Soos MA; George S; Berger D; Thomas EL; Bell JD; Meeran K; Ross RJ; Vidal-Puig A; Wareham NJ; O'Rahilly S; Chatterjee VK; Schafer AJ
Nat Genet; 2002 Aug; 31(4):379-84. PubMed ID: 12118251
[TBL] [Abstract][Full Text] [Related]
4. Resistance to thyroid hormone, and peroxisome-proliferator-activated receptor gamma resistance.
Chatterjee VK
Biochem Soc Trans; 2001 May; 29(Pt 2):227-31. PubMed ID: 11356159
[TBL] [Abstract][Full Text] [Related]
5. A dominant-negative peroxisome proliferator-activated receptor gamma (PPARgamma) mutant is a constitutive repressor and inhibits PPARgamma-mediated adipogenesis.
Gurnell M; Wentworth JM; Agostini M; Adams M; Collingwood TN; Provenzano C; Browne PO; Rajanayagam O; Burris TP; Schwabe JW; Lazar MA; Chatterjee VK
J Biol Chem; 2000 Feb; 275(8):5754-9. PubMed ID: 10681562
[TBL] [Abstract][Full Text] [Related]
6. Adipose-specific peroxisome proliferator-activated receptor gamma knockout causes insulin resistance in fat and liver but not in muscle.
He W; Barak Y; Hevener A; Olson P; Liao D; Le J; Nelson M; Ong E; Olefsky JM; Evans RM
Proc Natl Acad Sci U S A; 2003 Dec; 100(26):15712-7. PubMed ID: 14660788
[TBL] [Abstract][Full Text] [Related]
7. Peroxisome proliferator-activated receptor-gamma C190S mutation causes partial lipodystrophy.
Lüdtke A; Buettner J; Wu W; Muchir A; Schroeter A; Zinn-Justin S; Spuler S; Schmidt HH; Worman HJ
J Clin Endocrinol Metab; 2007 Jun; 92(6):2248-55. PubMed ID: 17356052
[TBL] [Abstract][Full Text] [Related]
8. Human metabolic syndrome resulting from dominant-negative mutations in the nuclear receptor peroxisome proliferator-activated receptor-gamma.
Savage DB; Tan GD; Acerini CL; Jebb SA; Agostini M; Gurnell M; Williams RL; Umpleby AM; Thomas EL; Bell JD; Dixon AK; Dunne F; Boiani R; Cinti S; Vidal-Puig A; Karpe F; Chatterjee VK; O'Rahilly S
Diabetes; 2003 Apr; 52(4):910-7. PubMed ID: 12663460
[TBL] [Abstract][Full Text] [Related]
9. Hypertension and abnormal fat distribution but not insulin resistance in mice with P465L PPARgamma.
Tsai YS; Kim HJ; Takahashi N; Kim HS; Hagaman JR; Kim JK; Maeda N
J Clin Invest; 2004 Jul; 114(2):240-9. PubMed ID: 15254591
[TBL] [Abstract][Full Text] [Related]
10. Tyrosine agonists reverse the molecular defects associated with dominant-negative mutations in human peroxisome proliferator-activated receptor gamma.
Agostini M; Gurnell M; Savage DB; Wood EM; Smith AG; Rajanayagam O; Garnes KT; Levinson SH; Xu HE; Schwabe JW; Willson TM; O'Rahilly S; Chatterjee VK
Endocrinology; 2004 Apr; 145(4):1527-38. PubMed ID: 14657011
[TBL] [Abstract][Full Text] [Related]
11. A novel heterozygous mutation in peroxisome proliferator-activated receptor-gamma gene in a patient with familial partial lipodystrophy.
Agarwal AK; Garg A
J Clin Endocrinol Metab; 2002 Jan; 87(1):408-11. PubMed ID: 11788685
[TBL] [Abstract][Full Text] [Related]
12. Inhibitory effect of a proline-to-alanine substitution at codon 12 of peroxisome proliferator-activated receptor-gamma 2 on thiazolidinedione-induced adipogenesis.
Masugi J; Tamori Y; Mori H; Koike T; Kasuga M
Biochem Biophys Res Commun; 2000 Feb; 268(1):178-82. PubMed ID: 10652233
[TBL] [Abstract][Full Text] [Related]
13. Peroxisome proliferator-activated receptor-gamma upregulates caveolin-1 and caveolin-2 expression in human carcinoma cells.
Burgermeister E; Tencer L; Liscovitch M
Oncogene; 2003 Jun; 22(25):3888-900. PubMed ID: 12813462
[TBL] [Abstract][Full Text] [Related]
14. Lessons from human mutations in PPARgamma.
Hegele RA
Int J Obes (Lond); 2005 Mar; 29 Suppl 1():S31-5. PubMed ID: 15711581
[TBL] [Abstract][Full Text] [Related]
15. The silent PPARgamma exon 6 CAC(His) --> CAT(His) polymorphism does not affect the plasma leptin levels in a collective of first degree relatives of type 2 diabetes patients from South West Germany.
Koch M; Rett K; Maerker E; Volk A; Haist K; Deninger M; Rettig A; Renn W; Häring HU
Exp Clin Endocrinol Diabetes; 2000; 108(5):341-6. PubMed ID: 10989952
[TBL] [Abstract][Full Text] [Related]
16. PPARG F388L, a transactivation-deficient mutant, in familial partial lipodystrophy.
Hegele RA; Cao H; Frankowski C; Mathews ST; Leff T
Diabetes; 2002 Dec; 51(12):3586-90. PubMed ID: 12453919
[TBL] [Abstract][Full Text] [Related]
17. PPAR(gamma) and glucose homeostasis.
Picard F; Auwerx J
Annu Rev Nutr; 2002; 22():167-97. PubMed ID: 12055342
[TBL] [Abstract][Full Text] [Related]
18. Unbuckling lipodystrophy from insulin resistance and hypertension.
Hegele RA; Leff T
J Clin Invest; 2004 Jul; 114(2):163-5. PubMed ID: 15254581
[TBL] [Abstract][Full Text] [Related]
19. Effect of heterozygous PPARgamma deficiency and TZD treatment on insulin resistance associated with age and high-fat feeding.
Miles PD; Barak Y; Evans RM; Olefsky JM
Am J Physiol Endocrinol Metab; 2003 Mar; 284(3):E618-26. PubMed ID: 12556354
[TBL] [Abstract][Full Text] [Related]
20. A new selective peroxisome proliferator-activated receptor gamma antagonist with antiobesity and antidiabetic activity.
Rieusset J; Touri F; Michalik L; Escher P; Desvergne B; Niesor E; Wahli W
Mol Endocrinol; 2002 Nov; 16(11):2628-44. PubMed ID: 12403851
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
